• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Elanco Finalizes Acquisition of Aratana Therapeutics

Share:

July 22, 2019

Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®.

This transaction allows Elanco to capture the full value of growing product Galliprant®, in which Elanco has had the exclusive rights to develop, manufacture and commercialize since 2016. Additionally, Aratana contributes two additional products to Elanco’s portfolio: Entyce®, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita®, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. Aratana’s research and development pipeline will also contribute to Elanco’s efforts to sustain the introduction of novel and innovative companion animal therapeutics.

“Aratana’s strong position in the specialty market – with their current portfolio and pipeline – complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” said Jeff Simmons, president and chief executive officer of Elanco. “This deal furthers Elanco’s value-generating IPP strategy (Innovation, Portfolio and Productivity) while continuing to bring great value to veterinarians and pet owners.”

Elanco has also begun the formation of a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. This specialty sales force makes Elanco unique – with a focus on serving an important and growing segment in veterinary care, and offering tailored products for the most complex and specialized approaches in veterinary medicine, like surgeries and oncology.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Date: July 22, 2019

Source: Elanco

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • UnitedCoatings Group Announces Acquisition of CoorsTek MedicalUnitedCoatings Group Announces Acquisition of CoorsTek Medical
  • Masimo Announces Agreement to Acquire TNI medical AGMasimo Announces Agreement to Acquire TNI medical AG
  • CVS Health to open 1,500 HealthHUB locations by 2021CVS Health to open 1,500 HealthHUB locations by 2021
  • Health Catalyst Joins the Partnership on AIHealth Catalyst Joins the Partnership on AI
  • New Lighthouse Initiative to Provide De-identified Patient Data for VIRUS COVID-19 RegistryNew Lighthouse Initiative to Provide De-identified Patient Data for VIRUS COVID-19 Registry
  • Yingli Pharma and MD Anderson Initiate Strategic Collaboration to Advance Development of Multiple Oncology ProgramsYingli Pharma and MD Anderson Initiate Strategic Collaboration to Advance Development of Multiple Oncology Programs
  • Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing ProgramsKorro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs
  • Turbine Secures €3 Million EUR Seed Fund to Expand the Potential of Simulation-first Drug DiscoveryTurbine Secures €3 Million EUR Seed Fund to Expand the Potential of Simulation-first Drug Discovery

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications